Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Safety, efficacy, and compliance of moderate-to-high dose eptinezumab and erenumab in chronic migraine patients with medication-overuse headache: an updated systematic review and meta-analysis

Fig. 2

Safety and Efficacy Outcomes of Eptinezumab and Erenumab (combined standard and high dose therapy). A: At least a 50% reduction in MMDs from baseline with at least 12 weeks of treatment. B: Remission of MOH with at 6 months of treatment. C: Risk of TESAEs. All analyses used a p value < 0.05, with 95% confidence intervals exclude null value of 1 as statistical significant results

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us